Exelixis Inc Gain (Loss) on Extinguishment of Debt
Exelixis Inc (EXEL) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2018-12-28, per its 10-K filed 2019-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2019-02-22
- Exelixis Inc gain (loss) on extinguishment of debt for the quarter ending 2018-12-28 was $0.00.
- Exelixis Inc gain (loss) on extinguishment of debt for the quarter ending 2018-09-28 was $0.00.
- Exelixis Inc gain (loss) on extinguishment of debt for the quarter ending 2017-12-29 was $0.00.
- Exelixis Inc gain (loss) on extinguishment of debt for the quarter ending 2017-09-30 was $0.00.
- Exelixis Inc gain (loss) on extinguishment of debt for fiscal 2018 was $0.00.
- Exelixis Inc gain (loss) on extinguishment of debt for fiscal 2017 was -$6.24M.
- Exelixis Inc gain (loss) on extinguishment of debt for fiscal 2016 was -$13.90M.
- Exelixis Inc gain (loss) on extinguishment of debt for fiscal 2016 was -$13.90M.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2018-12-28 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 10-K · filed 2019-02-22 | |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $0.00 10-Q · filed 2018-11-01 | ||
| 2018-06-29 | $0.00 10-Q · filed 2018-08-01 | |||
| 2017-12-29 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | -$6.24M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-01 | -$6.24M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$6.24M derived: sum of 2 quarters · filed 2018-11-01 | -$6.24M 10-Q · filed 2018-11-01 | |
| 2017-06-30 | -$6.24M 10-Q · filed 2017-08-02 | -$6.24M 10-Q · filed 2017-08-02 | ||
| 2016-12-31 | -$128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$13.90M derived: sum of 2 quarters · filed 2017-11-01 | -$13.90M derived: sum of 3 quarters · filed 2017-11-01 | -$13.90M 10-K · filed 2017-02-27 |
| 2016-12-30 | -$13.90M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | -$13.77M 10-Q · filed 2017-11-01 | -$13.77M derived: sum of 2 quarters · filed 2017-11-01 | -$13.77M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-02 | $0.00 10-Q · filed 2017-08-02 | ||
| 2016-01-01 | $0.00 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $0.00 derived: sum of 2 quarters · filed 2017-02-27 | $0.00 10-K · filed 2017-02-27 | |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-03 | $0.00 10-Q · filed 2016-11-03 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |